GlassScriptPhysician profile
Alafuro T Oruene
NPI 1649230491
$5,525.60
in general payments reported to CMS, 2019-2025
37 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $111 · 2021: $2,277 · 2022: $443 · 2023: $289 · 2024: $561 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,256.02 | 2020-2021 | |
| Redhill Biopharma INC. | $700.32 | 2021-2023 | Talicia, Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $576.11 | 2019-2025 | Relistor, Trulance |
| Forte Bio-Pharma LLC | $456.31 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Pfizer INC. | $391.94 | 2019-2025 | |
| Stimwave Technologies Incorporated | $387.60 | 2019 | |
| Daiichi Sankyo INC. | $213.24 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $150.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $143.00 | 2019-2024 | Airsupra |
| Novo Nordisk INC | $142.79 | 2021-2025 | |
| Abbvie INC. | $139.11 | 2023-2025 | |
| Abbott Laboratories | $133.83 | 2020-2021 | |
| Nalu Medical, INC. | $75.97 | 2022-2025 | Nalu Neurostimulation System |
| Scilex Pharmaceuticals INC. | $71.76 | 2022-2023 | Ztlido |
| Merz North America, INC. | $62.98 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $57.85 | 2023 | Givlaari |
| Collegium Pharmaceutical, INC. | $55.70 | 2020-2023 | Xtampza |
| Lilly USA, LLC | $54.16 | 2021-2023 | Reyvow, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $40.56 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $36.03 | 2024 | Fanapt |
| Kyowa Kirin, INC. | $33.71 | 2023 | Crysvita |
| Shionogi INC | $33.58 | 2019 | |
| Dexcom, INC. | $32.19 | 2024-2025 | Dexcom G6 Transmitter |
| Biodelivery Sciences International, INC. | $29.97 | 2020-2021 | |
| Spr Therapeutics, INC | $27.61 | 2024 | Sprint Pns System |
| Boston Scientific Corporation | $27.05 | 2021 | |
| Allergan, INC. | $26.12 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $22.47 | 2021 | |
| Inogen, INC. | $21.87 | 2022 | |
| Corcept Therapeutics | $19.39 | 2025 | Korlym |
| Averitas Pharma INC. | $18.40 | 2023 | Qutenza |
| Galderma Laboratories, L.P. | $17.82 | 2022 | |
| Biotronik Nro, INC. | $17.19 | 2024 | Prospera |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.11 | 2022 | |
| Medtronic USA, INC. | $15.97 | 2019 | |
| Amgen INC. | $15.87 | 2019 | |
| Electronic Waveform Lab, INC. | $3.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alafuro Oruene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.